Metformin and Gestational Diabetes

Overview of Metformin Use

Metformin is primarily prescribed for managing type 2 diabetes, but it is also utilized in the treatment of gestational diabetes, a condition characterized by elevated blood sugar levels that develop during pregnancy. Over the past decade, there has been a notable increase in the diagnosis of diabetes in young adults, parallel to a rise in the use of metformin among pregnant women.

Investigating Birth Defects

A key area of research has focused on whether metformin use during pregnancy is associated with an increased risk of birth defects. It is established that metformin crosses the human placenta, which means that the developing fetus is exposed to the medication. While metformin can influence cellular functions in the fetus, it remains uncertain if this exposure results in any birth defects.

Previous Research Limitations

Earlier studies have reported no correlation between metformin and birth defects. However, these studies often involved small participant groups and lacked robust design. To overcome these limitations, researchers from the Administrative Data Research Centre in Northern Ireland launched a comprehensive international study to investigate the potential effects of metformin exposure during pregnancy.

Study Findings

The research team gathered data from over 50,000 infants diagnosed with birth defects. They discovered that the likelihood of birth defects increased among mothers with diabetes; however, this risk did not extend to women with infertility or polycystic ovary syndrome (PCOS). Notably, only 168 infants in the study were exposed to metformin via the placenta.

The results indicated no significant increase in birth defects among babies exposed to metformin. The only defect that showed a significant association after statistical evaluation was pulmonary valve atresia, a rare cardiac abnormality. This specific defect is more commonly linked to maternal diabetes rather than the medication itself. Additionally, the low incidence of this birth defect suggests it may have occurred by chance.

Conclusion of the Study

The findings of this study suggest that metformin use during pregnancy does not elevate the risk of birth defects in infants. It is essential to consider that complications arise in studies involving pregnant women using metformin, especially since uncontrolled blood sugar levels in mothers can pose risks for birth defects. Any abnormalities noted in infants exposed to metformin are likely coincidental. Further research is necessary to validate the low risk or absence of cardiac abnormalities in infants whose mothers used metformin during pregnancy.

References

Given JE, Loane M, Garne E, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: Exploratory case-control study. BMJ. 2018. https://doi.org/10.1136/bmj.k2477
Friel, LA. Diabetes Mellitus in Pregnancy. Merck Manual. https://www.merckmanuals.com/en-ca/professional/gynecology-and-obstetrics/pregnancy-complicated-by-disease/diabetes-mellitus-in-pregnancy
Pinkerton, JV. Polycystic Ovary Syndrome (PCOS). Merck Manual. https://www.merckmanuals.com/en-ca/professional/gynecology-and-obstetrics/menstrual-abnormalities/polycystic-ovary-syndrome-pcos